CAR T-cell Design-dependent Remodeling of the Brain Tumor Immune Microenvironment Modulates Tumor-associated Macrophages and Anti-glioma Activity
Authors:
- Dalia HaydarDHDalia Haydar
- Jorge Ibañez-VegaJIJorge Ibañez-Vega
- Jeremy Chase CrawfordJCJeremy Chase Crawford
- Ching-Heng ChouCCChing-Heng Chou
- Clifford S. GuyCGClifford S. Guy
- Michaela MeehlMMMichaela Meehl
- Zhongzhen YiZYZhongzhen Yi
- Scott PerrySPScott Perry
- Jonathan LaxtonJLJonathan Laxton
- Trevor CunninghamTCTrevor Cunningham
- Deanna LangfittDLDeanna Langfitt
- Peter VogelPVPeter Vogel
Open Access
- 1 December 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 3 (12) , 2430-2446
Abstract
Understanding the intricate dynamics between adoptively transferred immune cells and the brain tumor immune microenvironment (TIME) is crucial for the development of effective T cell–based immunotherapies. In this study, we investigated the influence of the TIME and chimeric antigen receptor (CAR) design on the anti-glioma activity of B7-H3–specific CAR T-cells. Using an immunocompetent glioma model, we evaluated a panel of seven fully murine B7-H3 CARs with variations in transmembrane, costimulatory, and activation domains. We then investigated changes in the TIME following CAR T-cell therapy using high-dimensional flow cytometry and single-cell RNA sequencing. Our results show that five out of six B7-H3 CARs with single costimulatory domains demonstrated robust functionality in vitro. However, these CARs had significantly varied levels of antitumor activity in vivo. To enhance therapeutic effectiveness and persistence, we incorporated 41BB and CD28 costimulation through transgenic expression of 41BBL on CD28-based CAR T-cells. This CAR design was associated with significantly improved anti-glioma efficacy in vitro but did not result in similar improvements in vivo. Analysis of the TIME revealed that CAR T-cell therapy influenced the composition of the TIME, with the recruitment and activation of distinct macrophage and endogenous T-cell subsets crucial for successful antitumor responses. Indeed, complete brain macrophage depletion using a CSF1R inhibitor abrogated CAR T-cell antitumor activity. In sum, our study highlights the critical role of CAR design and its modulation of the TIME in mediating the efficacy of adoptive immunotherapy for high-grade glioma. Significance: CAR T-cell immunotherapies hold great potential for treating brain cancers; however, they are hindered by a challenging immune environment that dampens their effectiveness. In this study, we show that the CAR design influences the makeup of the immune environment in brain tumors, underscoring the need to target specific immune components to improve CAR T-cell performance, and highlighting the significance of using models with functional immune systems to optimize this therapy.Keywords
All Related Versions
Funding Information
- HHS | NIH | National Institute of Neurological Disorders and Stroke (R01NS121249)
- HHS | NIH | National Cancer Institute (K99CA256262)
- HHS | NIH | National Cancer Institute (R00CA256262)
- the Katzen Foundation (IRG22-973396)
This publication has 50 references indexed in Scilit:
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T CellsCancer Cell, 2015
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptorsNature Medicine, 2015
- Immunocompetent murine models for the study of glioblastoma immunotherapyJournal of Translational Medicine, 2014
- Design and development of therapies using chimeric antigen receptor‐expressing T cellsImmunological Reviews, 2013
- CSF-1R inhibition alters macrophage polarization and blocks glioma progressionNature Medicine, 2013
- T Cells Redirected to EphA2 for the Immunotherapy of GlioblastomaMolecular Therapy, 2013
- Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cellsBlood, 2010
- Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor EradicationMolecular Therapy, 2010
- The Immunological Genome Project: networks of gene expression in immune cellsNature Immunology, 2008
- Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapyCancer Science, 2006